Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.04M P/E - EPS this Y 97.20% Ern Qtrly Grth -
Income -24.14M Forward P/E -0.29 EPS next Y 56.40% 50D Avg Chg -24.00%
Sales - PEG 0.00 EPS past 5Y - 200D Avg Chg -79.00%
Dividend N/A Price/Book N/A EPS next 5Y 12.70% 52W High Chg -96.00%
Recommedations 2.00 Quick Ratio 0.44 Shares Outstanding 10.70M 52W Low Chg 22.00%
Insider Own 0.65% ROA -117.44% Shares Float 10.69M Beta 0.29
Inst Own 6.13% ROE - Shares Shorted/Prior 115.97K/14.11K Price 1.10
Gross Margin - Profit Margin - Avg. Volume 679,654 Target Price 7.00
Oper. Margin - Earnings Date Mar 29 Volume 40,322 Change -3.51%
About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.